A Trial to Evaluate the Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age

Inclusion criteria

• Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
• Written or witnessed/thumb printed informed consent obtained from the participant prior to performance of any trial-specific procedure.
• Healthy male and female participants between and including 50 through 64 YOA at the time of Informed consent form (ICF) signature.
• Female participants of childbearing potential may be enrolled if they practice adequate contraception and have a negative pregnancy test prior to study intervention administration.

Exclusion criteria

• History of microbiologically proven Invasive Pneumococcal Disease (IPD) caused by S. pneumoniae within the past 3 years.
• History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention(s).
• Any confirmed or suspected immunosuppressive or immunodeficient condition.
• Hypersensitivity to latex.
• Clinical conditions representing a contraindication to intramuscular vaccination, and blood collection.
• Documented history of Human immunodeficiency virus (HIV)-positive participant.
• Acute or unstable chronic clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, or metabolic conditions as determined by the investigator.
• Recurrent history of uncontrolled neurological or any neuroinflammatory disorders.
• Any behavioural or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with trial participation.
• History of potential immune-mediated disorders (pIMDs).
• Any other clinical condition that, might pose additional risk to the participant.
• Use of any investigational or non-registered product other than the study interventions during the period beginning 30 days before the study intervention administration.
• History of previous vaccination with any pneumococcal vaccine.
• Receipt of blood or plasma products or immunoglobulins, from 90 days before study intervention administration, or planned receipt within 30 days of study intervention administration.
• Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and/or planned use of long-acting immune-modifying treatments at any time up to the end of the trial.
• Pregnant or lactating female participant.
• History of chronic alcohol consumption and/or drug abuse, based on investigator judgment.